Clinical trials: Multiple Sclerosis, completed
Relapsing Remitting Multiple Sclerosis
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
Teva is developing a 40 mg/ml GA Injection, administered once daily under the skin, for the treatment of R-R MS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the…
- Trial name
- NCT00337779
- Testing
- Glatiramer Acetate (GA) 40 mg, glatiramer acetate 20 mg
- Volunteers
- 1,155 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Comprehensive Fall Prevention and Detection in Multiple Sclerosis
The purpose of this study is to examine whether an exercise and educational classroom program can help reduce falls in people with Multiple Sclerosis who fall frequently.
- Trial name
- FFF (NCT02583386)
- Testing
- Free From Falls fall prevention program, Electronic Fall Detector
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Portland VA Medical Center
Multiple Sclerosis
Low Load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis
The Primary Aim of this research study is to determine the feasibility of 8 weeks of physical therapy strengthening exercises using blood flow restriction (BFR) in people with multiple sclerosis (MS) who have moderate-to-severe…
- Trial name
- BFR-MS (NCT04633759)
- Testing
- Blood Flow Restriction Exercise
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
Relapsing Remitting MS, Secondary Progressive MS
Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis
Background/Rationale: Cognitive problems are a common symptom in individuals with Multiple Sclerosis (MS). Treatment options are limited, and there is a pressing need for new interventions to treat MS-related cognitive…
- Conditions
- Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
- Trial name
- NCT01848327
- Testing
- Caprylic Triglyceride
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- University of Miami
Multiple Sclerosis
Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.
This was a retrospective cohort study utilizing secondary data from IQVIA's open source pharmacy claims database (i.e., IQVIA LRx) selecting patients with prescription claims for ofatumumab or other DMTs of interest.
- Trial name
- NCT05576779
- Testing
- Ofatunumab
- Where
- United States
- Volunteers
- 2,101 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Anxiety
The Effect of Emotional Freedom Technique on Depression, Anxiety and Distress of Individuals With Multiple Sclerosis
Volunteers over the age of 18 who applied to the Neurology Outpatient Clinic of Dokuz Eylül University Hospital, who were diagnosed with multiple sclerosis in the last three months, one month after the initiation of treatment and…
- Conditions
- Multiple Sclerosis, Anxiety, Depressive Symptoms, Psychiatric Nursing
- Trial name
- NCT04969562
- Testing
- Emotional Freedom Technique
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Dokuz Eylul University
Multiple Sclerosis, Relapsing-Remitting
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
This is an open-label, randomized, multicenter, comparative, and parallel-group study comparing the therapeutic effects of two interferon-beta-1a regimens in relapsing-remitting multiple sclerosis (MS).
- Trial name
- NCT00292266
- Testing
- Rebif®, Avonex®
- Volunteers
- 677 people
- Sponsor
- EMD Serono
Nonmalignant Neoplasm, Tuberous Sclerosis
RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
This research study is evaluating a drug called rapamycin as a possible treatment for the lumps (or tumors) that form in the kidneys, called angiomyolipomas, in people who have either TSC or LAM.
- Conditions
- Nonmalignant Neoplasm, Tuberous Sclerosis, Lymphangioleimyomatosis, Kidney Angiomyolipoma
- Trial name
- NCT00126672
- Testing
- Rapamycin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Sclerosis
Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities
This study is being done to test the possible benefits of task-specific focused ankle training using the Ankle-Bot on subjects with Multiple Sclerosis who have "foot-drop." The study also compares the effectiveness of…
- Trial name
- NCT00906737
- Testing
- Ankle-bot, Conventional focused ankle therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mount Sinai Rehabilitation Hospital
Relapsing Forms of Multiple Sclerosis
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease…
- Trial name
- EPOC (NCT01216072)
- Testing
- Fingolimod, Standard MS DMTs
- Where
- 149 sites in United States, Canada and 1 more
- Volunteers
- 1,053 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis
This is an observational, non controlled, multicentric, prospective study planned to be conducted in 350 subjects diagnosed with multiple sclerosis (MS) in 20 centres of Argentina to identify the predictive factors leading to…
- Trial name
- NCT01079975
- Where
- Argentina
- Volunteers
- 301 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis
BCD-132 is a humanized monoclonal antibody against CD20. BCD-132-1 is a Multicenter Open-Label Non-Comparative Dose Escalation Study (Phase 1) of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 (JSC…
- Trial name
- NCT03551275
- Testing
- BCD-132
- Where
- 5 sites in Russia
- Volunteers
- 24 people
- Sponsor
- Biocad
Multiple Sclerosis
JC-Virus (JCV) Antibody Program
The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment.
- Trial name
- STRATIFY-1 (NCT01070823)
- Testing
- Tysabri® (natalizumab)
- Where
- 11 sites in United States
- Volunteers
- 1,096 people
- Sponsor
- Biogen
Multiple Sclerosis, COVID-19
COVID-19 Vaccine Biomarker Study in Multiple Sclerosis
SARS CoV-2 is the virus responsible for the pandemic COVID-19, which has resulted in nearly five million deaths worldwide since its spread in the beginning of 2020.
- Trial name
- NCT05121662
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Columbia University
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Trauma
Electric Stimulation of the Eye to Improve Vision After Trauma
Transcorneal Electrical Stimulation (TES) using the "OkuStim®" device delivers electrical impulses to damaged and/or diseased photoreceptor cells.
- Conditions
- Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), Trauma, Multiple Sclerosis (MS)
- Trial name
- TES (NCT02019927)
- Testing
- Transcorneal Electrical Stimulation
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Wills Eye
Multiple Sclerosis
Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis
This is a Phase IV, prospective, open-label, single-center, observational, longitudinal, single blinded study. The investigators will examine the effects of Ocrelizumab on cognitive, patient reported outcomes (PROs), quality of…
- Trial name
- NCT03025269
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University at Buffalo
Multiple Sclerosis
Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers
The primary objective of the study is to compare in healthy subjects, the GI tolerability of bioequivalent doses of Bafiertam™(monomethyl fumarate) and its pro-drug Tecfidera® (dimethyl fumarate).
- Trial name
- NCT04022473
- Testing
- Bafiertam, Tecfidera
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Multiple Sclerosis
Probiotic Intervention for People With Multiple Sclerosis
The goal of this single-arm, mixed methods trial is to learn if it is feasible and acceptable to take a probiotic for 12-weeks in people with Multiple Sclerosis.
- Trial name
- NCT07304713
- Testing
- Probiotic
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- Sheffield Hallam University
Multiple Sclerosis
Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis
The study is designed to quantitate McArdle's sign, an increase in measurable weakness with neck flexion described in patients with multiple sclerosis, and to determine whether it is or is not specific for multiple sclerosis.
- Trial name
- NCT03122873
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Multiple Sclerosis
tDCS for the Management of Multiple Sclerosis Related Fatigue
This is a pragmatic clinical trial that aims to determine the effect of tDCS on symptomatic fatigue in Multiple Sclerosis (MS) patients.
- Trial name
- NCT03838770
- Testing
- Active tDCS
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- NYU Langone Health